Skip to content

AGMB: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Agomab Therapeutics NV (AGMB)

Agomab Therapeutics NV

AGMB

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase2 readout (Ontunisertib): Dec 2028. Short interest: 2.6% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

Phase2 readout expected Dec 2028●●

Held by 4 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

4 specialist funds hold AGMB with a Phase 2 in 903 days for Ontunisertib (Fibrostenotic Crohn's Disease)

Perceptive Advisors Cormorant Asset Management Redmile Group Casdin Capital

Fund Holdings

4 fund convergence

Perceptive AdvisorsNew

Cormorant Asset ManagementNew

Redmile GroupNew

Casdin CapitalNew

AI Signal

Perceptive Advisors / AGMB – New Position Signal

Perceptive initiated a $6.3M position (600K shares) in Agomab Therapeutics, a clinical-stage biotech developing AGMB-129, an anti-PLAU antibody targeting fibrostenotic Crohn's disease — a high-unmet-need indication with no approved antifibrotic therapies. The key catalyst is a Phase 2 readout expected by September 2026, giving the position roughly a 12-15 month setup window.

Unlock full AI analysis — 14-day free trial

Position Trend

May 15, 2026

$43.8M

3 funds

May 29, 2026

$6.3M

1 fund

-86% total institutional value over 2 quarters

Short Interest

High short interest

Short Shares

1.07M

Change

+38.7%

Days to Cover

12.9

% of Float

2.6%

Settlement

Jun 15, 2026

Short interest over 7 periods

Catalysts

Phase 2Q4 2028OntunisertibFibrostenotic Crohn's DiseaseNCT07683325

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GRedmile Group5.6%May 15, 2026

SC 13GCormorant Asset Management5.0%May 15, 2026

Position Details

Perceptive AdvisorsNEW POSITIONMay 29, 2026

Start free trialfor share counts, dollar values & AI analysis

3 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

COGT1 fund ENGNW1 fund CTNM1 fund CBIO1 fund ENSCW1 fund MDLN1 fund MGTX1 fund NAUT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: